Floatz logo

17 assets in Post-Transplant Lymphoproliferative Disease

Therapeutic assets addressing Post-Transplant Lymphoproliferative Disease, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cyclophosphamide
Post-Transplant Lymphoproliferative Disease
Washington University School of MedicineP2BBB (72)
Rituximab
Post-Transplant Lymphoproliferative Disease
Jennifer AmengualP2BB (69)
Fludarabine
Post-Transplant Lymphoproliferative Disease
City of Hope Medical CenterP2BB (68)
Lenalidomide
Post-Transplant Lymphoproliferative Disease
Northwestern UniversityP2B (63)
Brentuximab Vedotin
Post-Transplant Lymphoproliferative Disease
Yale UniversityP2B (60)
Epcoritamab
Post-Transplant Lymphoproliferative Disease
Northwestern UniversityP2B (58)
Tabelecleucel
Post-Transplant Lymphoproliferative Disease
Pierre Fabre MedicamentP2B (57)
Etoposide
Post-Transplant Lymphoproliferative Disease
City of Hope Medical CenterP1CCC (53)
Valganciclovir
Post-Transplant Lymphoproliferative Disease
Viracta Therapeutics, Inc.P2CCC (53)
Donor-Derived Ex-Vivo Expanded Ebv Tscm Ctl
Post-Transplant Lymphoproliferative Disease
University Hospital, Basel, SwitzerlandP1/2CCC (48)
Polatuzumab Vedotin
Post-Transplant Lymphoproliferative Disease
Washington University School of MedicineP1/2CC (47)
qs-21
Post-Transplant Lymphoproliferative Disease
Ohio State University Comprehensive Cancer CenterP1CC (43)
Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tcm-Enriched T Cells
Post-Transplant Lymphoproliferative Disease
City of Hope Medical CenterP1CC (41)
Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes
Post-Transplant Lymphoproliferative Disease
City of Hope Medical CenterP1CC (41)
Bendamustine
Post-Transplant Lymphoproliferative Disease
City of Hope Medical CenterP1CC (41)